QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:AMLX

Amylyx Pharmaceuticals (AMLX) Stock Forecast, Price & News

$25.51
-0.74 (-2.82%)
(As of 05:51 PM ET)
Compare
Today's Range
$25.03
$26.34
50-Day Range
$24.04
$31.42
52-Week Range
$12.39
$41.93
Volume
677,756 shs
Average Volume
935,313 shs
Market Capitalization
$1.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.17

Amylyx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
96.7% Upside
$50.17 Price Target
Short Interest
Bearish
20.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Amylyx Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$17.32 M Sold Last Quarter
Proj. Earnings Growth
650.00%
From $0.42 to $3.15 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

72nd out of 986 stocks

Pharmaceutical Preparations Industry

28th out of 478 stocks


AMLX stock logo

About Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMLX Stock News Headlines

Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch
Amylyx Pharmaceuticals is the rare young biotech that's profitable. The company earned $0.02 a share in Q1, and analysts expect profitability to grow.
Master the Market: Free Stock Analysis + Buy/Sell/Hold Signals!
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Master the Market: Free Stock Analysis + Buy/Sell/Hold Signals!
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Analyzing Amylyx Pharmaceuticals (AMLX) & Its Rivals
See More Headlines

AMLX Price History

AMLX Company Calendar

Last Earnings
3/13/2023
Today
6/09/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMLX
Fax
N/A
Employees
296
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.17
High Stock Price Forecast
$54.00
Low Stock Price Forecast
$47.00
Forecasted Upside/Downside
+91.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-198,380,000.00
Pretax Margin
-158.55%

Debt

Sales & Book Value

Annual Sales
$22.23 million
Book Value
$5.14 per share

Miscellaneous

Free Float
58,645,000
Market Cap
$1.76 billion
Optionable
Not Optionable
Beta
-0.86

Key Executives

  • Mr. Joshua B. Cohen (Age 31)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. Justin B. Klee (Age 32)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. James M. Frates M.B.A. (Age 56)
    Chief Financial Officer
    Comp: $695.12k
  • Ms. Gina M. Mazzariello (Age 52)
    Chief Legal Officer & Gen. Counsel
    Comp: $794.83k
  • Mr. Tom Holmes
    Chief Technical Operations Officer
  • Ms. Shauna Horvath
    Head of Global Marketing
  • Ms. Debra L. Canner (Age 64)
    Global Head of HR & CHRO
  • Ms. Margaret M. Olinger M.B.A (Age 58)
    Global Head of Commercial & Chief Commercial Officer
  • Dr. Patrick D. Yeramian M.D. (Age 64)
    MBA, Ph.D., Global Head of Clinical R&D and Chief Medical Officer
  • Mr. Chris Aiello
    Head of Canada & GM













AMLX Stock - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMLX shares.
View AMLX analyst ratings
or view top-rated stocks.

What is Amylyx Pharmaceuticals' stock price forecast for 2023?

6 brokers have issued 12 month target prices for Amylyx Pharmaceuticals' shares. Their AMLX share price forecasts range from $47.00 to $54.00. On average, they anticipate the company's stock price to reach $50.17 in the next year. This suggests a possible upside of 91.1% from the stock's current price.
View analysts price targets for AMLX
or view top-rated stocks among Wall Street analysts.

How have AMLX shares performed in 2023?

Amylyx Pharmaceuticals' stock was trading at $36.95 at the beginning of the year. Since then, AMLX shares have decreased by 29.0% and is now trading at $26.25.
View the best growth stocks for 2023 here
.

Are investors shorting Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 8,530,000 shares, an increase of 24.2% from the April 30th total of 6,870,000 shares. Based on an average daily volume of 948,300 shares, the days-to-cover ratio is currently 9.0 days. Currently, 20.1% of the shares of the company are short sold.
View Amylyx Pharmaceuticals' Short Interest
.

When is Amylyx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our AMLX earnings forecast
.

How were Amylyx Pharmaceuticals' earnings last quarter?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced its earnings results on Monday, March, 13th. The company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.12. The company had revenue of $21.89 million for the quarter, compared to analyst estimates of $3.05 million.

When did Amylyx Pharmaceuticals IPO?

(AMLX) raised $190 million in an IPO on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share.

What is Amylyx Pharmaceuticals' stock symbol?

Amylyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLX."

Who are Amylyx Pharmaceuticals' major shareholders?

Amylyx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (8.99%), BlackRock Inc. (5.39%), Federated Hermes Inc. (2.75%), Pictet Asset Management SA (2.14%), State Street Corp (1.59%) and Emerald Advisers LLC (1.45%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian.
View institutional ownership trends
.

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amylyx Pharmaceuticals' stock price today?

One share of AMLX stock can currently be purchased for approximately $26.25.

How much money does Amylyx Pharmaceuticals make?

Amylyx Pharmaceuticals (NASDAQ:AMLX) has a market capitalization of $1.76 billion and generates $22.23 million in revenue each year. The company earns $-198,380,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis.

How many employees does Amylyx Pharmaceuticals have?

The company employs 296 workers across the globe.

How can I contact Amylyx Pharmaceuticals?

The official website for the company is amylyx.com. The company can be reached via phone at 617-682-0917 or via email at investors@amylyx.com.

This page (NASDAQ:AMLX) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -